[Phase II clinical study of a new anticancer drug boanmycin].
OBJECTIVE
To evaluate the efficacy of boanmycin (BAM) in patients with advanced cancers.


METHODS
A multicenter phase II clinical study on BAM was conducted on 105 cases received BAM as single agent, and 220 cases were treated with combination chemotherapy containing BAM.


RESULTS
The total response rate was 35.0% for single agent and 64.2% for combination chemotherapy group in advanced cancers. The response rate for single agent in malignant lymphoma, cancer of head and neck and breast cancer was 66.7%, 65.0% and 37.5%, respectively; and for combination chemotherapy group in malignant lymphoma, breast cancer, head and neck cancer, esophageal cancer and lung cancer was 88.5%, 62.5%, 50.0%, 47.2% and 45.8%, respectively. The main side effects with mild or moderate fever, chill, myalgia, gastrointestinal reactions, skin pigmentation as well as hardening of skin at injection site.


CONCLUSIONS
BAM therapy was effective in malignant lymphoma, cancer of head and neck and other cancers.
Feng
F
F
Department of Medical Oncology, Cancer Hospital, CAMS and PUMC, Beijing 100021.
Zhou
L
L
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
C052656:bleomycin A6; D001761:Bleomycin